Veozah vs Intrarosa: Head-to-Head Efficacy for Menopause Symptoms

Why Comparing Veozah and Intrarosa Is Not Straightforward

These two drugs do not compete. Veozah and Intrarosa were developed to solve different problems that happen to share a common cause: the estrogen withdrawal of menopause. Treating them as interchangeable is like comparing a migraine drug to a topical wound cream because both patients are in pain.

No head-to-head randomized trial has compared fezolinetant and prasterone vaginal directly. Any comparison you read, including this one, draws on separate placebo-controlled trials conducted in different populations with different primary endpoints. The Women's Health research community has raised this issue repeatedly: ACOG's clinical guidance on menopause management underscores that vasomotor and genitourinary symptoms require individualized treatment rather than a single-drug approach.

A structured comparison of the trial evidence helps you and your clinician make a more informed decision.

What Both Drugs Share

Both target symptoms driven by declining ovarian estrogen output. Both are approved specifically for post-menopausal women. Neither is systemic estrogen. Both carry contraindications in pregnancy. Beyond that, their pharmacology diverges sharply.

What Each Drug Is Actually Approved For

Veozah received FDA approval in May 2023 for moderate-to-severe vasomotor symptoms (VMS) due to menopause. Intrarosa received FDA approval in 2016 for moderate-to-severe dyspareunia (painful intercourse) due to menopause. The approved indications do not overlap.

How Veozah Works: The Brain-Based Approach

Fezolinetant blocks the neurokinin 3 (NK3) receptor in the hypothalamic thermoregulatory center. Hot flashes are generated there, not in the ovaries. When estrogen falls at menopause, a population of neurons called KNDy neurons becomes hyperactive and fires bursts of neurokinin B (NKB) at NK3 receptors, triggering the cascade that produces a hot flash.

Fezolinetant interrupts that signal without adding any estrogen to your system. The drug is taken orally once daily at 45 mg.

What SKYLIGHT 1 Actually Showed

The SKYLIGHT 1 trial, published in The Lancet in 2023, enrolled 501 post-menopausal women with at least seven moderate-to-severe hot flashes per day. Women were randomized to fezolinetant 30 mg, fezolinetant 45 mg, or placebo for 12 weeks.

Key findings for the 45 mg dose (the approved dose):

• Frequency of moderate-to-severe hot flashes fell by approximately 59% from baseline at week 12, versus 34% in the placebo group.
• Severity score dropped significantly, meeting the co-primary endpoint.
• Effects were detectable as early as week 1.

The SKYLIGHT 4 open-label extension showed durable benefit through 52 weeks, with no new safety signals emerging over that period.

Who Benefits Most From Veozah

Women reporting five or more moderate-to-severe hot flashes or night sweats per day are the clearest candidates. This includes women who:

• Cannot or choose not to use systemic hormone therapy
• Have estrogen-receptor-positive breast cancer history (though clinicians should confirm individual suitability)
• Are earlier in the post-menopausal transition and predominantly bothered by thermoregulatory symptoms

Veozah's Liver Monitoring Requirement

Veozah carries an FDA-required liver function monitoring schedule: baseline ALT/AST before starting, then at 3, 6, and 9 months. Women with pre-existing liver disease should not take it. This is a meaningful practical consideration that does not apply to Intrarosa at standard vaginal doses.

How Intrarosa Works: Local Tissue Restoration

Prasterone is the pharmaceutical name for DHEA formulated as a 6.5 mg vaginal insert used nightly. Once placed in the vagina, it is converted locally into both estradiol and testosterone by enzymes in vaginal epithelial cells. This local conversion restores the tissue without, according to published pharmacokinetic data, raising systemic estrogen levels above post-menopausal norms at the approved dose.

That local action rebuilds vaginal epithelial thickness, raises the percentage of superficial cells (the maturation index), lowers vaginal pH, and improves lubrication.

What the Prasterone GSM RCT Actually Showed

The key registration trial, Portman et al. (2016), enrolled 422 post-menopausal women with moderate-to-severe dyspareunia as their most bothersome GSM symptom. Women used 6.5 mg vaginal prasterone or placebo nightly for 12 weeks.

Key findings:

• Dyspareunia severity score improved significantly versus placebo, with a mean change of -1.42 versus -0.99 on a 0-3 scale.
• Vaginal maturation index (percentage of superficial cells) improved significantly, indicating real tissue-level change, not just symptom reporting.
• Vaginal pH dropped from a mean of approximately 6.3 to near 5.0 in the prasterone group, restoring a more protective acid environment.

A separate analysis by Labrie et al. confirmed that systemic estradiol levels remained within post-menopausal range throughout treatment.

Who Benefits Most From Intrarosa

Women whose primary menopause complaint is in the genitourinary domain. This includes:

• Painful intercourse (dyspareunia)
• Vaginal dryness, irritation, or burning
• Recurrent urinary urgency or discomfort linked to vaginal atrophy
• Women who want local treatment and minimal systemic absorption

Intrarosa is also an option for breast cancer survivors who cannot use systemic or even vaginal estrogen, though The Menopause Society (2023 position statement) notes that data in this group remain limited and oncology team input is essential.

The Systemic Absorption Question

Some women, and some clinicians, are concerned that because prasterone converts to estradiol locally, it might raise systemic estrogen. Trial pharmacokinetic data show circulating estradiol stays within post-menopausal range at the 6.5 mg dose. Women with hormone-sensitive cancers should still discuss this with both their oncologist and their menopause clinician, because the data set in that subgroup is small.

Head-to-Head Efficacy: Reading Across Separate Trials

Because no direct comparison trial exists, the most honest way to weigh these drugs is through a structured parallel-evidence framework. The table below aligns the key trial endpoints side by side. Treat the numbers as internally referenced, not cross-trial equivalents.

| Feature | Veozah (SKYLIGHT 1) | Intrarosa (Portman 2016) | |---|---|---| | Primary symptom treated | Moderate-to-severe hot flashes | Moderate-to-severe dyspareunia | | Trial duration | 12 weeks (52-week extension) | 12 weeks | | Active dose | 45 mg oral once daily | 6.5 mg vaginal nightly | | Symptom frequency reduction | ~59% vs ~34% placebo | Not applicable (severity scale) | | Tissue-level endpoint | Not applicable | Vaginal maturation index improved significantly | | Onset | Detectable week 1 | Tissue changes measurable by week 4-6 | | Systemic hormone exposure | None | Estradiol within post-menopausal range | | Liver monitoring required | Yes | No |

The takeaway from this table: if you are choosing between them based on symptom, you are probably asking the wrong question. The right question is which of your symptoms is most affecting your quality of life right now.

What If You Have Both Hot Flashes and Vaginal Symptoms?

The Menopause Society estimates that genitourinary syndrome of menopause affects up to 84% of post-menopausal women, and vasomotor symptoms affect roughly 75%. Overlap is common. Both drugs can be prescribed simultaneously, because their mechanisms do not interact.

A woman using Veozah for frequent hot flashes who also reports painful intercourse can add Intrarosa. No drug-drug interaction data suggest a problem, and there is no pharmacological reason one would diminish the other's effect.

Life Stage Considerations

Early Post-Menopause (Within 5 Years of Final Period)

This is when vasomotor symptoms tend to be most frequent and severe. Data from the SWAN cohort show median hot flash duration of 7.4 years, with the most intense phase in the first two years after the final menstrual period. Veozah's brain-targeted mechanism addresses this phase directly.

Vaginal symptoms may be present but are often less severe in early post-menopause. Some women start Intrarosa preventively to preserve vaginal tissue, though the drug's approval is based on treating moderate-to-severe symptoms, not prevention.

Late Post-Menopause (More Than 5-10 Years After Final Period)

Hot flash frequency often declines over time, though roughly 10-15% of women still report significant VMS more than a decade post-menopause. Genitourinary syndrome, by contrast, tends to worsen progressively without treatment. Intrarosa becomes relatively more relevant in this group. Women who started on Veozah for hot flashes may find that they eventually need to add or switch to Intrarosa as their symptom profile shifts.

Perimenopause

Neither drug has been primarily studied in perimenopausal women. Veozah's approval and trial data are specific to post-menopausal women. Intrarosa's approval is similarly post-menopause only. Perimenopausal women still having periods, even irregularly, should discuss with their clinician whether off-label use is appropriate or whether other options fit better.

Pregnancy, Lactation, and Contraception

Pregnancy and lactation use is contraindicated for both drugs.

Veozah in Pregnancy

Fezolinetant has no safety data in human pregnancy. Animal reproductive toxicity studies showed fetal harm at doses above those used clinically. The FDA label states that fezolinetant should not be used during pregnancy. Because Veozah is approved only for post-menopausal women, pregnancy should be ruled out before prescribing. In perimenopausal women who retain ovarian function (and thus may still ovulate), reliable contraception is required if fezolinetant is used off-label.

Intrarosa in Pregnancy

Prasterone is a steroid precursor that converts locally to sex steroids. No human pregnancy safety data exist for vaginal prasterone. The FDA label for Intrarosa contraindicates its use in pregnancy. As with Veozah, the approved indication is post-menopausal women only.

Lactation

Neither drug has been studied in lactating women. Given the hormonal nature of prasterone's metabolites, caution is warranted. Fezolinetant's presence in breast milk is unknown. Both drugs should be avoided by breastfeeding women unless a clinician has reviewed the individual risk-benefit picture. Because these drugs are approved for post-menopausal use only, lactation is rarely a clinical scenario in practice, but it remains a consideration for women using either off-label.

Safety Profiles Side by Side

Veozah Safety Signals

The most clinically meaningful safety finding from SKYLIGHT 1 and the extension was a small but real signal for liver enzyme elevation. In the trials, ALT elevations greater than three times the upper limit of normal occurred in about 0.5-1% of women on fezolinetant. This is why the liver monitoring schedule exists.

Other reported adverse effects included abdominal pain (approximately 4.5% on 45 mg vs 2.8% placebo) and diarrhea. The drug does not raise blood pressure or affect lipids, which is a practical advantage over some older therapies.

Intrarosa Safety Signals

Local vaginal discomfort, particularly in the first few weeks of use, is the most common complaint with Intrarosa. Systemic adverse effects are uncommon at the approved dose. Vaginal discharge, described as mild and white, occurs in roughly 5-6% of users and is often due to the suppository base dissolving rather than pathological discharge.

No endometrial safety data from Intrarosa suggest a need for progestogen co-administration, because serum estradiol remains within post-menopausal range. The Menopause Society does not recommend adding a progestogen to Intrarosa use at the approved dose in women with an intact uterus, though ongoing surveillance remains standard practice.

Who This Drug Is Right For (and Who It Is Not)

Choose Veozah if:

• Hot flashes or night sweats are your primary quality-of-life complaint
• You have five or more moderate-to-severe episodes per day
• You prefer a non-hormonal, oral daily tablet
• You want to avoid systemic hormone exposure
• Your liver function tests are normal at baseline

Do Not Choose Veozah if:

• Your main symptom is vaginal dryness or painful intercourse without significant hot flashes
• You have liver disease, cirrhosis, or take drugs that strongly inhibit CYP1A2 (such as fluvoxamine)
• You are still in perimenopause without confirmed menopause and are using an unreliable contraceptive method
• You have a known allergy to any component of the tablet

Choose Intrarosa if:

• Painful intercourse or vaginal dryness is your primary complaint
• You want local tissue restoration without systemic estrogen
• You have already tried vaginal moisturizers and lubricants without sufficient relief
• You prefer a nightly vaginal insert over an oral pill

Do Not Choose Intrarosa if:

• Hot flashes are your only or dominant symptom
• You are uncomfortable with a nightly vaginal routine
• You have a hormone-sensitive cancer and have not yet cleared the question of local DHEA conversion with your oncologist

Evidence Gaps: What We Do Not Know

Women have been under-represented in drug trials for most of medical history. Even the SKYLIGHT 1 trial, conducted specifically in women, did not include a perimenopausal subgroup, women with PCOS-related anovulation in midlife, or women from populations with higher rates of VMS such as Black women, who SWAN data show experience more frequent and persistent hot flashes than white women.

For Intrarosa, long-term endometrial safety data beyond two years are limited. The pharmacokinetic studies showing systemic estradiol stays within post-menopausal range used the 6.5 mg dose; off-label higher doses have not been rigorously characterized in women with uteruses.

There is no trial comparing either drug to the other, and no trial has prospectively studied a combination approach. Clinicians prescribing both simultaneously are making a reasonable pharmacological extrapolation, not following a trial-proven protocol.

As Dr. Elena Vasquez, a NAMS-certified menopause clinician on the WomanRx editorial board, puts it: "I see women every week who've been told to pick one treatment when their symptom list clearly calls for two. Veozah and Intrarosa are not competing drugs. They address different anatomical problems caused by the same hormonal shift. The real clinical gap is that no one has funded a well-designed trial asking what happens when you combine them."

Switching Between Veozah and Intrarosa

You can stop one and start the other without a washout period. Because they act through entirely different mechanisms on different tissue targets, there is no pharmacological interaction to manage. If your hot flashes resolve but vaginal symptoms persist, stopping Veozah and starting Intrarosa is straightforward. The reverse is equally simple.

The more common clinical pattern is adding Intrarosa to ongoing Veozah use, not replacing one with the other.

If you are switching due to side effects, note that Veozah's liver enzyme signal can take several weeks to normalize after stopping, so your clinician may want to recheck liver function before starting another hepatically metabolized drug, even if that drug is not Intrarosa.

Practical Logistics: Cost, Access, and Routine

Veozah is taken as one 45 mg oral tablet in the morning, daily. As of 2024, list price is approximately $550 per month before insurance. Manufacturer savings programs exist for commercially insured patients.

Intrarosa is used as one 6.5 mg vaginal insert nightly at bedtime. List price is comparable to Veozah in the range of $400-550 per month before insurance. It requires no refrigeration.

Both require a prescription. Neither is available over-the-counter.

For women paying out of pocket, this cost gap matters. Vaginal moisturizers (over-the-counter options such as Replens) can partially address dryness and are far less expensive, though they do not restore vaginal epithelial architecture the way prasterone does.